Morning Briefing
News & Observer - Raleigh,NC,USA
Biogen Idec's multiple sclerosis drug Tysabri will be spotlighted today when the biotechnology company releases its latest financial results. ...
See all stories on this topic

Biogen's Steady Growth
Motley Fool - USA
Revenue in the quarter was up a healthy 17% year over year, as revenue from its multiple sclerosis franchise drugs, Avonex and Tysabri, continue to pick up ...
See all stories on this topic

Tysabri backing by NICE significant milestone for UK's ...
Pharmaceutical Business Review - USA
However, the decision by the National Institute for Health and Clinical Excellence to recommend Tysabri for a severe form of MS could rejuvenate this ...
See all stories on this topic